Clinical trials: Irritation
Irritable Bowel Syndrome
Mesalazine Therapy in Patients With Irritable Bowel Syndrome
The purpose of this study is to determine whether Mesalazine is effective in the treatment of the abdominal discomfort or pain of Irritable Bowel Syndrome patients.
- Trial name
- IBS-02/07 (NCT00626288)
- Testing
- Mesalazine
- Where
- 22 sites in Italy
- Volunteers
- 187 people
- Sponsor
- SOFAR S.p.A.
Irritable Bowel Syndrome
Inuline Supplement in Patients With Irritable Bowel Syndrome
The study investigate the efficacy of the combination inuline, choline and silymarin in alleviating the symptomatology of the patients with irritable bowel syndrome with constipation in a randomized, cross-over, no treatment…
- Trial name
- NCT03174561
- Testing
- Inuline, Choline and Silymarin, diet restriction
- Where
- Romania
- Volunteers
- 50 people
- Sponsor
- SC Fiterman Pharma SRL
Alzheimer Disease
REXULTI General Use Results Survey in Patients With Hyperactivity, or Aggressive Behavior Associated With Alzheimer's Dementia
The purpose of this study is to evaluate safety of REXULTI in patients under daily clinical settings. In addition, information on efficacy will be collected.
- Trial name
- NCT06875986
- Testing
- Brexpiprazole (Rexulti)
- Where
- Japan
- Volunteers
- 200 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Irritable Bowel Syndrome
Investigation of the Safety and Efficacy of Renzapride in Constipation Predominant Irritable Bowel Syndrome (IBS)
The purpose of the study is to investigate whether renzapride will help alleviate the symptoms associated with constipation predominant irritable bowel syndrome in female patients.
- Trial name
- NCT00268879
- Testing
- Renzapride
- Where
- United Kingdom
- Volunteers
- 1,821 people
- Sponsor
- Alizyme
Irritable Bowel Syndrome
A Study of 3 Doses of Dextofisopam in Females With Irritable Bowel Syndrome
The primary objectives of this study are to evaluate the clinical safety and tolerability and to assess the efficacy of 100 mg, 200 mg, and 300 mg BID dextofisopam compared with placebo in female outpatients with…
- Trial name
- NCT00486876
- Testing
- Dextofisopam
- Where
- 79 sites in United States
- Volunteers
- 324 people
- Sponsor
- Pharmos
IBS - Irritable Bowel Syndrome
Lifestyle Eating and Performance (LEAP) Program for the Treatment of Irritable Bowel Syndrome (IBS)
A three month follow-up study to evaluate the effectiveness of a tailored anti-inflammatory eating plan guided by a registered dietitian to treat irritable bowel syndrome.
- Trial name
- NCT05178017
- Testing
- Leukocyte Activation Assay (LAA-MRT) / Lifestyle Eating and Performance (LEAP) program
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Oxford Biomedical Technologies, Inc.
Hygiene
Dermacyd PH_DETINLYN (Lactic Acid) Tangerine Mix - Compatibility
The purpose of this study is to demonstrate the absence of irritation potential (primary dermic irritability and cumulated dermic irritability) and allergy (sensibilization) of the product Dermacyd PHDETINLYN Tangerine Mix.None.
- Trial name
- NCT00786097
- Testing
- Dermacyd PH_DETINLYN (Lactic Acid)
- Where
- Brazil
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Sanofi
Irritable Bowel Syndrome
Assessment of the Symbiotic Fermented Milk in Patients With Irritable Bowel Syndrome
This study evaluates the effect of a symbiotic fermented milk on health-related quality of life and irritable bowel syndrome (IBS) symptoms in patients with constipation-predominant IBS.
- Trial name
- NCT02391220
- Testing
- LCA symbiotic fermented milk, heat-treated fermented milk
- Volunteers
- 76 people
- Sponsor
- Clinres Farmacija d.o.o.
Fragile X Syndrome
Biomarker Testing and DNA Collection in Subjects Participating in Protocol 22001
The subjects that meet the inclusion and exclusion criteria and consent to participate in protocol 22001 will be offered participation in 22001A which will evaluate secreted protein before and after treatment with STX209 and…
- Trial name
- NCT00823368
- Testing
- STX209
- Where
- 11 sites in United States
- Sponsor
- Seaside Therapeutics, Inc.
Hygiene
Dermacyd PH_DETINBACK Tangerine Mix (Lactic Acid) - Photo Evaluation
The purpose of this study is to demonstrate the absence of photoirritation and photosensitization potential of the product Dermacyd PHDETINBACK Tangerine Mix (Lactic Acid).
- Trial name
- NCT00783666
- Testing
- Lactic Acid (Dermacyd PH_DETINBACK Tangerine Mix)
- Where
- Brazil
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Sanofi
Aggressive Behavior in Fragile X Syndome
Inhibition of Aggressive Behavior in Participants With Fragile X Syndrome
The goal of this clinical trial is to learn if drug SRX246 works to treat irritability, agitation, aggression and self-injury (IAAS) behaviors in adult males with Fragile X Syndrome (FXS).
- Trial name
- NCT07328529
- Testing
- SRX246
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- Azevan Pharmaceuticals
Healthy Volunteers
A Study to Evaluate the Skin Irritation Potential of PBI-100 Topical Cream in Healthy Participants
This is an open-label, single-arm, randomized, evaluator-blinded repeat insult patch testing (RIPT) study wherein test product is applied under an occlusive dressing to the upper back or arm continuously and repeatedly to the…
- Trial name
- NCT04882631
- Testing
- PBI-100 Topical Cream, Positive Control - Sodium laurel sulfate (SLS), PBI-100 Topical Cream, Vehicle
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Pyramid Biosciences
Osteoporosis, Postmenopausal
A Multiple-Dose Study to Evaluate Skin Irritation and Sensitization of Teriparatide Administered Transdermally in Healthy Postmenopausal Women
This study is a Phase 1, multi-center, 2-part, subject- and investigator-blind, randomized, placebo-controlled, multiple dose study of transdermal teriparatide (80-µg dose) in healthy postmenopausal women.
- Trial name
- NCT01250145
- Testing
- LY333334
- Where
- 5 sites in United States, Germany and 1 more
- Volunteers
- 251 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Irritable Bowel Syndrome With Diarrhea (IBS-D)
G-PUR® for Symptomatic Treatment in Irritable Bowel Syndrome With Diarrhea
A randomized, double-blind, placebo-controlled pilot study in patients with IBS-D according to Rome IV criteria evaluating the clinical efficacy and safety of oral administration of 2g G-PUR® tid compared to placebo in a cohort…
- Trial name
- NCT04138186
- Testing
- 2.0g G-PUR®, oral administration
- Where
- Austria
- Volunteers
- 30 people
- Sponsor
- Glock Health, Science and Research GmbH
Irritable Bowel Syndrome
Efficacy and Safety of Alflorex Bei Reizdarm in Patients With Irritable Bowel Syndrome
This Post-Market Clinical-Follow Up (PMCF) study gains data on the efficacy and safety of "Alflorex bei Reizdarm", a probiotic based on Bifidobacterium longum 35624, in the daily use by irritable bowel syndrome (IBS) patients.
- Trial name
- NCT04859075
- Testing
- Bifidobacterium longum 35624
- Where
- Germany
- Volunteers
- 37 people
- Sponsor
- Medice Arzneimittel Pütter GmbH & Co KG
Irritation Potential of Topic Agent
A Study to Evaluate the Irritation Potential of ATx201 in Healthy Volunteers
This is a Phase I single-site study to evaluate the irritation potential of topically applied ATx201 GEL, 2% and 4%, along with positive and negative control and placebo control (ATx201 GEL Placebo), in healthy human subjects on…
- Trial name
- NCT03301870
- Testing
- ATx201 Gel 2%, ATx201 Gel 4%, Positive Control
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- UNION therapeutics
Onychomycosis
Cumulative Irritation Test
The purpose of this study is to determine the cumulative irritation potential of the products listed by the Sponsor.
- Trial name
- NCT00680095
- Testing
- AN2690, AN2690 Solution, Vehicle, Sodium Lauryl Sulfate, 0.5%
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Pfizer
Irritable Bowel Syndrome
Efficacy, Safety and Tolerability of DNK333 (25 and 100 mg Bid) in Women With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
This study will evaluate the tolerability, safety and efficacy of DNK333 against diarrhea caused by Irritable Bowel Syndrome in women.
- Trial name
- CDNK333B2201 (NCT00699166)
- Testing
- DNK333
- Where
- 29 sites in United States
- Volunteers
- 135 people
- Sponsor
- Novartis
Healthy
Dermacyd Tina Gel Sweet Flower - Photo Evaluation
The purpose of this study is to prove the absence of photo irritation and photo sensitivity potential of the product Dermacyd Tina Gel Sweet Flower.
- Trial name
- NCT00668629
- Testing
- Lactic acid (Dermacid)
- Where
- Brazil
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Sanofi
Irritable Colon
Safety and Efficacy Study of GR68755 (Alosetron Hydrochloride) to Treat Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS)
This study is an exploratory study aiming (i) to obtain clinical experience of GR68755 in Japanese subjects with severe d-IBS to explore the feasibility of the next phase study and (ii) to obtain reference data for endpoints and…
- Trial name
- NCT01855711
- Testing
- GR68755 (Alosetron hydrochloride) 1 mg tablet
- Volunteers
- 32 people
- Sponsor
- GlaxoSmithKline